. Author manuscript; available in PMC: 2009 Jul 1.

Published in final edited form as: J Pharmacol Exp Ther. 2008 Apr 25;326(1):286–295. doi: 10.1124/jpet.108.139675

Table 5.

SoRI Compounds Noncompetitively Inhibit [³H]DA Uptake

Condition	V_MAX (Percent of Control)	Apparent K_M (nM)
A. SoRI-20040
Control	100±7	36.8±1.4
0.8 μM	74±7^*	50.7±2.2^*
3.2 μM	39±2^*	48.6±3.0^*
12.8 μM	22±2^*	50.4±5.0^*
B. SORI-20041
Control	100±5	52.9±3.0
0.8 μM	30±2^*	65.7±5.1^*
3.2 μM	22±4^*	78.5±8.9^*
12.8 μM	16±2^*	87.4±9.0^*
C. SORI-2827
Control	100±7^*	41.7±2.1
0.8 μM	98±7	72.1±2.3^*
3.2 μM	92±6	89.8±3.5^*
12.8 μM	68±4^*	84.6±5.6^*

Uptake binding surfaces were generated as described in Methods in the absence and presence of the indicated concentrations of test drugs. The data of 3 experiments (132 data points) were pooled and fit to the one component uptake equation for the best-fit estimates of the V_max and K_m. Each value is ±SD, n=3.

p<0.01 (F-test).